Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.54 |
| ▸ | CASR | P41180 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3674695 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2SCN8ACASRHTTCYP3A4 | |
| SCHEMBL23754497 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2SCN8ACASRHTTCYP3A4 | |
| SCHEMBL23754619 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2SCN8ACASRHTTCYP3A4 | |
| SCHEMBL17465588 | 0.83 | SCN8A (0.41) | SMN1; SMN2SCN8ACASRHTTCYP3A4 | |
| SCHEMBL3679074 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2SCN8ACASRHTTCYP3A4 | |
| SCHEMBL3679075 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2SCN8ACASRHTTCYP3A4 | |
| SCHEMBL28846531 | 0.81 | HTT (0.55) | SMN1; SMN2CASRHTTCYP3A4LMNA | |
| SCHEMBL23754499 | 0.81 | HTT (0.55) | SMN1; SMN2CASRHTTCYP3A4LMNA | |
| SCHEMBL17108551 | 0.78 | ADRA2C (0.41) | SCN8ACYP3A4LMNASLC6A4HTR2B | |
| SCHEMBL14469578 | 0.76 | SMN1; SMN2 (0.82) | SMN1; SMN2CASRHTTCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884509-B1 | OPTICALLY ACTIVE 3-METHYLCYCLOPENTADECANONE AND METHOD FOR PRODUCING INTERMEDIATE THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-7728177-B2 | Optically active 3-methylcyclopentadecanone and method for producing intermediate thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20090124826-A1 | 2-cyclopentadecen-1-one is subjected to a 1,4-conjugate addition reaction of a methyl group by using a methylated organic metal ( dimethylzinc) in presence of a catalyst (trifluoromethanesulfonic acid, cu salt), an enol anion scavenger(propionic anhydride), a specific optically active phosphoramidite | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-1884509-A1 | OPTICALLY ACTIVE 3-METHYLCYCLOPENTADECANONE AND METHOD FOR PRODUCING INTERMEDIATE THEREOF | Takasago International Corporation (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124826-A1 | 2-cyclopentadecen-1-one is subjected to a 1,4-conjugate addition reaction of a methyl group by using a methylated organic metal ( dimethylzinc) in presence of a catalyst (trifluoromethanesulfonic acid, cu salt), an enol anion scavenger(propionic anhydride), a specific optically active phosphoramidite | CPN1, CAPN1, MCOLN1 | SMN1; SMN2 1957/4885SCN8A 3162/4885CASR 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.